Challenges and Opportunities in Lentivirus Viral Vector Manufacturing for In Vivo Applications.

Area of Science:

• Biotechnology
• Gene Therapy
• Oncology

Background:

• Chimeric antigen receptor (CAR) T-cell therapies show clinical success but face manufacturing barriers.
• In vivo cell therapy using lentiviral vectors (LVVs) offers a cost-effective alternative to ex vivo methods.
• Transitioning to in vivo applications necessitates advancements in LVV biomanufacturing for safety and efficacy.

Purpose of the Study:

• To examine critical bottlenecks in current lentiviral vector (LVV) production for in vivo applications.
• To identify challenges in upstream and downstream processing affecting LVV purity and function.
• To highlight the need for improved analytical methods for therapeutic LVV assessment.

Main Methods:

• Analysis of LVV particle assembly, maturation, and the impact of transgene size on functional titers.
• Investigation of non-functional byproduct formation, including empty particles and extracellular vesicles (EVs).
• Evaluation of downstream processing challenges for labile LVV particles and current analytical assay limitations.

Main Results:

• Impurities like empty LVVs and EVs pose risks of immunotoxicity and insertional mutagenesis.
• Purification of labile LVVs requires rapid, high-resolution techniques such as continuous processing.
• Current assays struggle to differentiate functional LVVs from inactive contaminants.

Conclusions:

• Developing novel purification strategies based on biophysical differences (e.g., surface charge, capsid morphology) is essential.
• Implementing robust, high-throughput analytics is critical for ensuring the delivery of high-purity, potent therapeutic LVVs.
• Advancements in LVV biomanufacturing are key to realizing the potential of in vivo lentiviral therapy.